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Abstract
Background: A number of reports have demonstrated that rodents immunized with DNA vaccines can
produce antibodies and cellular immune responses presenting a long-lasting protective immunity. These
findings have attracted considerable interest in the field of DNA vaccination. We have previously described
the prophylactic and therapeutic effects of a DNA vaccine encoding the Mycobacterium leprae 65 kDa heat
shock protein (DNA-HSP65) in a murine model of tuberculosis. As DNA vaccines are often less effective
in humans, we aimed to find out how the DNA-HSP65 stimulates human immune responses.
Methods: To address this question, we analysed the activation of both human macrophages and dendritic
cells (DCs) cultured with DNA-HSP65. Then, these cells stimulated with the DNA vaccine were evaluated
regarding the expression of surface markers, cytokine production and microbicidal activity.
Results: It was observed that DCs and macrophages presented different ability to uptake DNA vaccine.
Under DNA stimulation, macrophages, characterized as CD11b+/CD86+/HLA-DR+, produced high levels
of TNF-alpha, IL-6 (pro-inflammatory cytokines), and IL-10 (anti-inflammatory cytokine). Besides, they also
presented a microbicidal activity higher than that observed in DCs after infection with M. tuberculosis. On
the other hand, DCs, characterized as CD11c+/CD86+/CD123-/BDCA-4+/IFN-alpha-, produced high levels
of IL-12 and low levels of TNF-alpha, IL-6 and IL-10. Finally, the DNA-HSP65 vaccine was able to induce
proliferation of peripheral blood lymphocytes.
Conclusion: Our data suggest that the immune response is differently activated by the DNA-HSP65
vaccine in humans. These findings provide important clues to the design of new strategies for using DNA
vaccines in human immunotherapy.
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Background
DNA vaccination has arisen as a safe and effective strategy
for inducing protective cell and humoral immunity in pre-
clinical models of infectious diseases [1,2]. These vaccines
are able to activate the innate immune system, even in the
absence of an adjuvant. It is assumed that they interact
with the pattern recognition receptor Toll-like receptor 9
(TLR9) through unmethylated CpG oligodeoxynucle-
otides (CpG ODNs) present on plasmid backbone [3,4].
Downstream, TLR9 interacts with the adaptor molecule
MyD88 (myeloid differentiation factor 88), and the acti-
vation of MyD88 leads to the activation of several tran-
scription factors, resulting in the up-regulation of cytokine
and chemokine gene expression [5-8]. In relation to adap-
tive immune response, there are at least three mechanisms
by which the antigen encoded by plasmid DNA is proc-
essed and presented to elicit immune response: (I) direct
priming by somatic cells [9]; (II) direct transfection of
professional antigen-presenting cells (APCs) [10-12]; and
(III) cross-priming in which plasmid DNA transfects a
somatic cell and/or a professional APC and the secreted
protein is taken up by other professional APC and pre-
sented to T cells [13-16].
Early studies conducted in mice showed that DNA vacci-
nation conferred protection against pathogen challenge
[17-20]. Experimental data collected by our group over
the last few years have shown that the DNA vaccine
encoding the Mycobacterium leprae 65 kDa heat shock pro-
tein (DNA-HSP65) has prophylactic and therapeutic
effects in a murine model of TB [17,19,21,22]. The pro-
phylactic effect initially obtained from this vaccine was
equal to that elicited by live BCG vaccine in mice and this
protection was associated with the presence of CD8+/
CD44hi IFN-gamma – producing cytotoxic cells [17,19].
Additionally, we demonstrated that DNA vaccine can be
taken up by CD11b+(macrophages) and CD11c+ (DC)
cells, as well as by B lymphocytes after its administration
in mice [23]. However, several studies in nonhuman pri-
mates and human clinical trials have suggested that DNA
vaccines are not nearly as immunogenic in these species as
they are in rodents [24-27]. Therefore, a better under-
standing of how DNA-HSP65 vaccine activates human
immune response was taken into account herein.
Thus, the aim of this study was to compare the immune
responses of human macrophages and DCs induced
byDNA-HSP65 vaccine. These professional APCs drive the
activation of T lymphocytes and are thought to be the
most important stimulators of adaptive immune response
to antigens. We compared the immune response induced
by DNA-HSP65 vaccine in vitro through the evaluation of
surface markers, cytokine production and microbicidal
activity of human macrophages and DCs. Additionally,
the capacity of DNA-HSP65 to activate the adaptive
immune response was evaluated. The data reported herein
provide important implications for the design of new vac-
cination strategies, which may contribute to the use of
DNA plasmid in human immunotherapy.
Methods
Monoclonal antibodies
The mAbs specific for CD80 (clone BB1) coupled to fluo-
rescein isothiocyanate (FITC), CD86 (clone IT2.2), HLA-
DR (clone G46-6), CD83 (clone HB15e), coupled to phy-
coerythrin (PE), CD11b (clone ICRF44), CD11c (clone B-
ly6), and CD123 (clone 9F5) coupled to Cy-chrome, were
purchased from BD (BD, San Diego, CA, USA). The mAbs
specific for CD1c (clone AD5-8E7) and BDCA-4 (clone
AD5-17F6) coupled to PE were obtained from Miltenyi
Biotec (Auburn, CA, USA). The purified mAb TLR9
(26C593 clone) was obtained from Imgenex (San Diego,
CA, USA), and the biotinylated anti-mouse IgG was
obtained from Bioscience (Toronto, Canada).
Plasmid construction and purification
DNA-HSP65 vaccine was derived from pVAX vector (Inv-
itrogen, Carlsbad, CA, USA), which had previously been
digested with BamHI and Not I (Invitrogen), and a 3.3-kb
fragment (corresponding to the M. leprae HSP65 gene)
was inserted. The vector pVAX was used as a control. Plas-
mids were replicated in DH5alpha Escherichia coli and
purified with Endofree Plasmid Giga kit (Qiagen, Valen-
cia, CA, USA) according to the manufacturer's protocol.
Endotoxin levels were determined using a QCL-1000
Limulus amoebocyte lysate kit (Cambrex Company,
Walkersville, MD, USA), and were less than 0.1 endotoxin
units (EU)/μg DNA.
Plasmid DNA labelling
The DNA vaccine was labeled with Alexa Fluor 594 or
Alexa Fluor 488 by Universal Linkage System (ULS™)
using the ULYSIS nucleic acid labelling kit (Invitrogen,
Molecular Probe) as previously described [23]. The con-
formation of labeled plasmid was not altered.
Cell cultures
Peripheral blood mononuclear cells (PBMCs) were
obtained from blood donated by healthy volunteers at the
Fundação Hemocentro de Ribeirão Preto (Ribeirão Preto
Haemocentre Foundation, Ribeirão Preto, Brazil). This
work was approved by Comitê de Ética em Pesquisa do
Hospital das Clínicas de Ribeirão Preto (Ethic Committee
Research from Ribeirão Preto Clinical Hospital, Brazil).
Mononuclear cells were separated by density gradient cen-
trifugation using Ficoll-Paque (GE Life Sciences, Uppsala,
Sweden). Monocytes were purified by density gradient
centrifugation using Percoll (GE Life Sciences). Macro-
phages and DCs were differentiated by culturing mono-Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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cytes in 24-well tissue culture plates (Corning, Corning,
NY, USA) with 1 ng/mL of GM-CSF (BD) or with 14 ng/
mL of IL-4 (BD) and 7 ng/mL of GM-CSF, respectively, for
7 days at approximately 1 × 106 cells/mL in RPMI 1640
(Sigma-Aldrich) supplemented with 10% foetal bovine
serum (FBS) (Invitrogen, Gibco), streptomycin/ampicil-
lin (Invitrogen, Gibco) and gentamicin (Invitrogen,
Gibco). Plasmacytoid dendritic cells (pDCs) were purified
from PBMCs by positive selection with immunomagnetic
microbeads (Miltenyi Biotec, Auburn, CA, USA) based on
BDCA-4 expression.
Fluorescence microscopy
An amount of 5 × 104 macrophages and DCs were stimu-
lated with 5 μg of Alexa Fluor 594-labeled DNA vaccine
for 4 h for uptake assays. These cells were mounted on
glass coverslips with Cell-tak (BD, New Bedford, MA,
USA) with Fluormount-G (Electron Microscopy Sciences)
and analysed with a Nikon Eclipse E800 fluorescence
microscope (Nikon USA, Melville, NY). Images were
acquired with a Nikon DXM-1200 digital camera (Nikon
USA) connected to the microscope.
Confocal microscopy
Macrophages, myeloid and plasmacytoid DCs were
placed onto Cell-Tak-coated glass coverslips (BD Bio-
sciences, New Bedford, MA, USA), fixed with 4% parafor-
maldehyde (Electron Microscopy Sciences, Fort
Washington, PA, USA) for 15 min at 37°C, and permeabi-
lised with 0.3% Triton X-100 (Sigma-Aldrich) for 10 min
at 25°C. The cells were washed with 0.1 M glycine (Sigma-
Aldrich) for 5 min, and then labeled with purified mAb
anti-TLR9 (5 μg/mL) (Imgenex) for 30 min at 4°C. Subse-
quently, the cells were incubated with biotinylated anti-
mouse IgG (7.5 μg/mL; Bioscience) for 1 h at room tem-
perature. Finally, cells were incubated with streptavidin
conjugated to Alexa Fluor 488 (Molecular Probes, Eugene,
OR, USA) for 30 min, mounted on glass slides with Fluor-
mount (Electron Microscopy Sciences) and examined
with a Leica TCS SP2 AOBS (Leitz, Manheim, Germany).
FACS analysis
Macrophages and DCs were stimulated with 20 μg/mL of
DNA vaccine or DNA vector over a 48 h period to evaluate
cell surface phenotype. Additionally, 500 ng/mL of LPS
(Salmonella typhimurium, Sigma) was used as positive con-
trol of cellular activation. To study the capacity of the cells
to uptake DNA, macrophages and DCs were stimulated
with Alexa Fluor 488-labeled DNA vaccine for 1 h. Then,
the cells were analysed by flow cytometry (FACSort, Bec-
ton Dickinson, San Jose, CA, USA). A biparametric gate in
the forward (FSC) and side scatter (SSC) dot plot was
drawn around the macrophages or DCs populations.
Approximately 4000 Mac-1+ (macrophages) or CD11c+
(DC) cells were acquired. The computer analysis was
made using the Cell-Quest program (version 3.3).
Cytokine secretion
Supernatants from macrophages and DCs cultures stimu-
lated with DNA vaccine, DNA vector or LPS were har-
vested at 48 h after stimulation. Cytokine levels were
determined by ELISA using recombinant cytokines for
generating standard curves. Purified mAb anti-TNF-alpha
(clone Mab1), anti-IL-6 (clone MQ2-13A5), anti-IL-10
(clone JES3-19F1), anti-IL-12p40 (clone C8.3), as well as
biotinylated mAb anti-TNF-alpha (clone Mab11), anti-IL-
6 (clone MQ2-39C3), anti-IL-10 (clone JES3-12G8), and
anti-IL-12p40 (clone C8.6) were obtained from BD and
used according to the manufacturer's instructions. Addi-
tionally, supernatants from cultures of monocyte-derived
DCs and peripheral blood pDCs were assayed for IFN-
alpha detection by Interferon-alpha ELISA Kit, (Immuno-
Biological Laboratories, Minneapolis, MN, USA).
Culture of M. tuberculosis and infection of macrophages 
and DCs
M. tuberculosis H37Rv (ATCC n° 27294) was obtained
from an aliquot frozen at -70°C. Fifty microliters of this
aliquot (viability greater than 85%) were cultured in
Lowenstein-Jensen medium for 20–30 days at 37°C. M.
tuberculosis was then added to 10 mL of 7H9 medium
(Difco, BD, Detroit, USA) and incubated for 7–10 days at
37°C. After analysis of viability, the bacilli number was
determined by optic density of the culture at 540 nm. The
bacterial suspension was then centrifuged at 4000 × g for
20 min and the pellet was diluted in RPMI 1640 supple-
mented with 10% FBS and antibiotic-free. Macrophages
and DCs were infected with M. tuberculosis with a multi-
plicity of infection (MOI) of 1 bacillus per 1 cell (MOI =
1). Four hours after infection the supernatants were
removed, the cells were washed, centrifuged at 900 × g for
10 min and then lysed with a solution of 0,25% SDS-PBS
(J.T. Baker, Phillipsburg, NJ, USA). Serial dilutions were
plated in Middlebrook 7H11 agar medium. The same pro-
cedure was performed at 7 days after infection. The colony
forming units (CFU) were counted after 20–30 days.
RT-PCR for mRNA Hsp65 detection
Total RNA was isolated from PBMCs by extraction in Tri-
zol Reagent (Invitrogen) and alcohol precipitation, fol-
lowed by an additional treatment with DNAse I
amplification grade (Invitrogen) to avoid genomic and
plasmid DNA contamination. Total RNA (1 μg) was
reverse transcribed using oligo(dT) primers and reverse
transcriptase (Invitrogen) according to the manufacturer
instructions. The PCR amplification was carried out using
3 μL of cDNA preparation and specific primer pairs of M.
leprae  Hsp65 (sense 5'-TCAAGGTGGCGTTGGAAGC-3'
and antisense 5'-CCGTGACCCACTGAAAGGTTA-3'; giv-Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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ing a 103-bp band). Samples were submitted to 35 cycles
of amplification in a PTC-200 Peltier Thermal Cycler (MJ
Research Inc., Watertown, MA, USA). In each cycle, dena-
turation was performed at 95°C for 45 sec, primers were
annealed to target cDNA at 65°C for 40 sec, and extension
was carried out at 72°C for 90 sec. Messenger RNA for
beta-actin was detected by PCR using cDNA and beta-
actin-specific primers (sense 5' ATGTTTGAGACCT-
TCAACA-3' and antisense 5'-CACGTCAGACTTCAT-
GATGG-3'; giving a 495-bp band). The PCR products were
visualised by ultraviolet illumination after electrophoresis
on a 1% agarose gel containing ethidium bromide.
PBMC proliferation assay
A total of 2 × 105 PBMCs were stained with 5-(and-6)-car-
boxyfluorescein diacetate, succinimidyl ester (CFSE; Invit-
rogen, Molecular Probes) and plated in 96 well round
bottom culture plate (Corning) in RPMI 1640 (Sigma-
Aldrich) supplemented with 10% autologous serum,
streptomycin/ampicillin (Invitrogen, Gibco) and gen-
tamicin (Invitrogen, Gibco). PBMCs were cultured during
7 days with recombinant Hsp65 or during 12 days with
DNA vaccine or vector. Additionally, PBMC were cultured
with recombinant Hsp65 plus DNA vaccine or vector dur-
ing 12 days. The cells were then harvested and evaluated
for their CFSE content by flow cytometry. As positive con-
trol, PBMCs were stimulated with phytohemagglutinin. A
gate in FSC and SSC dot plot was drawn around the lym-
phoblast population and the frequency of CFSE-contain-
ing cells was determined.
Statistical analysis
Data are expressed as means ± SEM. Statistical significance
of differences was determined by the unpaired Student's t-
test. Differences which provided P < 0.05 were considered
to be statistically significant. Statistical analyses were per-
formed by using PRISM software (version 4.0; GraphPad,
San Diego, CA, USA).
Results
Characterization of immature DCs and macrophages
Freshly isolated monocytes cultured with GM-CSF differ-
entiate into macrophages, whereas those cultured with
GM-CSF plus IL-4 differentiate into DCs. As expected,
macrophages and DCs differed morphologically. Macro-
phages were characterized as large and adherent cells,
while DCs were round, smaller than macrophages and
presented cytoplasmic extensions (dendrites) (data not
shown). Macrophages and DCs were characterized as
CD11b+ and CD11c+ cells, respectively. Both CD11b+ and
CD11c+ cells constitutively expressed CD86 and HLA-DR
molecules (Figures 1A and 1B). We further observed that
17% of DCs were characterized as CD11c+CD1c+ and 98%
were CD11c+  BDCA-4+. CD123, a receptor exclusively
expressed by plasmacytoid dendritic cells (pDCs), was not
detected on the surface of either CD1c+ or BDCA-4+ cells
(Figure 1C). Moreover, we also evaluated the IFN-alpha
production by these cells. An experimental control was
performed with pDCs. The pDCs stimulated with DNA
vaccine secreted higher levels of IFN-alpha in comparison
to the unstimulated pDCs (Figure 1D). On the other
hand, monocyte-derived DCs did not secrete IFN-alpha.
In order to analyse the expression of TLR9 by macro-
phages and DCs, confocal microscopy was used (Figure
1E). It was found that monocyte-derived macrophages
and DCs displayed strong cytoplasmic staining for TLR9,
indicating its presence in intracellular compartments.
pDCs isolated from peripheral blood were stained and
used as positive control for TLR9 expression. These results
were confirmed by flow cytometry analyses (data not
shown).
Uptake of DNA vaccine by macrophages and DCs
To determine whether human macrophages and DCs
would be able to taken up naked DNA-HSP65, we stimu-
lated cells with fluorescent-labeled DNA vaccine. Four
hours after stimulation with naked DNA-HSP65, fluores-
cent endocytic vesicles were observed in the cytoplasm of
macrophages and DCs (Figure 2A), suggesting that the
plasmid was taken up by these cells during this period.
Flow cytometry analyses showed that macrophages and
DCs had different ability to taken up naked DNA vaccine
(Figure 2B). The DNA vaccine or vector was uptaken by
almost 100% of macrophages CD11b+ and by approxi-
mately 85% of DCs CD11c+. The analysis of median fluo-
rescence intensity, which indicates the ability to take up
DNA on a per-cell basis, show that DCs behaved with a
bimodal pattern: while a subpopulation of CD11c+ cells
displayed low uptake rates, the other one presented high
uptake capacity. These values were similar when the cells
were stimulated with either vaccine or vector. These
results suggest that the uptake of DNA-HSP65 vaccine or
vector by DCs was higher than that observed in macro-
phages.
Activation of the innate immune response induced by 
DNA-HSP65
In order to study the activation of innate immune
response mediated by DNA-HSP65, human macrophages
and DCs stimulated with the DNA vaccine were evaluated
regarding the cytokine production, expression of surface
markers and microbicidal activity. In relation to cellular
phenotype, we did not observe any variation in the
number of DNA vaccine-stimulated macrophages express-
ing HLA-DR, CD80 or CD86 molecules (Figure 3A) or
changes in the median fluorescence intensity (data not
shown). Conversely, the stimulation of DCs with DNA
vaccine resulted in an up-regulation of CD80, CD86 and
CD83 (a maturation marker) expression (Figure 3A). AfterGenetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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Phenotypic characterization of monocyte-derived macrophages and DCs Figure 1
Phenotypic characterization of monocyte-derived macrophages and DCs. (A) Expression of markers CD11b (Mac-
1), CD86 and HLA-DR on the surface of macrophages, and (B) CD11c, CD86 and HLA-DR on the surface of DCs was evalu-
ated by flow cytometry (all markers are indicated by solid lines). Dotted-line histograms indicate isotype control mAb. These 
results are representative of seven independent experiments. (C) Expression of CD1c, CD123 (IL-3 receptor) and BDCA-4 on 
the surface of DCs. (D) IFN-alpha production by monocyte-derived DC (mo-DC) and plasmacytoid DC (pDC). These results 
are representative of three independent experiments. (E) Intracellular expression of TLR9 by macrophages and DCs analysed 
by confocal microscopy.Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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Uptake of DNA-HSP65 by macrophages (Mφ) and DC Figure 2
Uptake of DNA-HSP65 by macrophages (Mφ) and DC. (A) Cells were stimulated for 4 h with Alexa Fluor 594-labeled 
DNA-HSP65 and analysed by fluorescence microscopy. Endocytic vesicles are indicated by white arrows. (B) Differential capac-
ity of macrophages and DCs to uptake DNA vaccine. Cells were stimulated for 1 h with Alexa Fluor 488-labeled DNA-HSP65 
and analysed by flow cytometry. These results are representative of three independent experiments. Black line: stimulated 
cells; dotted line: non-stimulated cells.Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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stimulation with DNA vaccine or DNA vector, no differ-
ence was seen in the number of DCs expressing HLA-DR.
In all experiments LPS was used as positive control of cel-
lular activation.
Regarding the cytokines production, macrophages stimu-
lated with DNA vaccine secreted levels of TNF-alpha, IL-6
and IL-10 significantly higher than those of the unstimu-
lated cells. Similar levels of these cytokines were secreted
by vector-stimulated cells (Figure 3B). Notably, vaccine-
stimulated macrophages did not produce either IL-12p40
(Figure 3B) or IL-12p70 (data not shown). In contrast,
vaccine or vector-stimulated DCs provided significantly
higher levels of TNF-alpha and IL-12p40 than those pro-
vided by the unstimulated cells. The production of TNF-
alpha by DCs was also observed in experiments that were
carried out with immunostimulatory CpG, an additional
control (data not shown). DCs produced lower levels of
TNF-alpha, IL-6 and IL-10 compared to macrophages.
To evaluate whether the activation induced by DNA-
HSP65 could increase the microbicidal capacity of macro-
phages and DCs against M. tuberculosis, these cells were
stimulated with DNA vaccine or vector and then were
infected. Figure 3C shows that unstimulated macrophages
were more permissive to M. tuberculosis growth when
compared to macrophages that had been stimulated with
DNA vaccine or DNA vector. On day 7 after infection, the
bacterial load of the unstimulated infected macrophages
differed significantly from that recovered on day 0 (after 4
Activation of the innate immune response mediated by DNA-HSP65 Figure 3
Activation of the innate immune response mediated by DNA-HSP65. (A) Expression of costimulatory molecules and 
HLA-DR on the surface of macrophages (Mφ) and DC stimulated with DNA vaccine. Cells were stimulated with DNA vaccine, 
DNA vector or LPS (positive control). After 48 h stimulation, the expression of surface molecules was evaluated by flow 
cytometry. Each column represents the mean percentage of Mφ or DC positive for CD80, CD86 or HLA-DR, or DC positive 
for CD83 ± SEM. Cells were obtained from 11 cultures of Mφ and 7–9 cultures of DC from different healthy individuals. (B) Mφ 
and DC were incubated for 48 h with DNA vaccine, DNA vector or LPS and the production of TNF-alpha, IL-6, IL-10 and IL-
12p40 was evaluated. Each column represents the mean ± SEM of cytokine production detected in 6–8 Mφ cultures or 7–10 
DC cultures obtained from healthy donors. *p < 0.05; **p < 0.01; ***p < 0.001, in relation to non-stimulated Mφ. #p < 0.05; 
##p < 0.01; ###p < 0.001, in relation to non-stimulated DC. (C) Intracellular growth of M. tuberculosis in Mφ or DCs stimu-
lated with DNA-HSP65. Mφ and DCs were stimulated with DNA vaccine or DNA vector (both at 20 μg/mL) for 48 h and 
infected with M. tuberculosis at MOI = 1. CFU numbers were determined at 4 h (day 0) and 7 days (day 7) after infection. 
Results represent the mean ± SEM of five experiments (for DCs) or three experiments (for Mφ). * p < 0,05, when compared 
to CFU numbers recovered on days 0 and 7 postinfection.Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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h). However, the number of CFU recovered from macro-
phages that had previously been stimulated with DNA
vaccine or vector was similar at 0 and 7 days postinfection.
When we analysed the mycobacterial growth in cultures of
DCs that had previously been stimulated with DNA vac-
cine or DNA vector, we observed that the CFU number
was similar to that detected in unstimulated DC cultures.
It is interesting to note that bacilli growth was higher in
unstimulated macrophages than in unstimulated DCs,
despite the fact that a similar number of bacilli were
detected within both cells after 4 h of infection (12,1 × 104
± 5,9 × 104 and 10,7 × 104 ± 6,1 × 104 CFU, respectively).
These data show that while macrophages secreted high
levels of TNF-alpha, IL-6 and IL-10 after DNA-HSP65
stimulation, DCs secreted IL-12 and up-regulated the
expression of CD80, CD86 and CD83. Moreover, the
stimulation of human macrophages with DNA-HSP65
seems to improve its microbicidal potential against M.
tuberculosis, since we did not find significant difference
between CFU numbers after 4 h and 7 d of infection. On
the other hand, DCs were unable to kill intracellular M.
tuberculosis after being stimulated with DNA-HSP65.
Activation of the adaptive immune response induced by 
DNA-HSP65
To investigate the ability of DNA-HSP65 to activate adap-
tive immune response, the proliferation of PBMC induced
by the DNA vaccine was determined. For this purpose,
CFSE-labeled PBMC were stimulated with DNA vaccine or
vector and analysed by flow cytometry. As positive control
of specific proliferation, PBMC were stimulated with
recombinant Hsp65 protein (rHsp65). The mRNA for
Hsp65 was detected in monocytes cultured for 96 h with
DNA-HSP65 (Figure 4A). DNA-HSP65 induced signifi-
cant proliferation of PBMC compared to unstimulated
cells. On the other hand, DNA vector was unable to
induce a significant proliferation of PBMC (Figure 4B).
Recombinant Hsp65 protein did not exhibit an additional
effect on PBMC proliferation induced by DNA-HSP65.
Figure 4C shows the histograms and is representative of
Activation of adaptive immune response induced by DNA-HSP65 Figure 4
Activation of adaptive immune response induced by DNA-HSP65. (A) Expression of Hsp65 mRNA by monocytes 
stimulated with DNA vaccine or vector was evaluated by RT-PCR. (B) Proliferation of PBMCs after stimulation with DNA-
HSP65. CFSE-labeled PBMCs were cultured with DNA vaccine, vector or with recombinant Hsp65 (rHsp65). Cell proliferation 
was determined by flow cytometry. Results represent the mean ± SEM of nine experiments. * p < 0,05, when compared to 
unstimulated cells. (C) Representative histograms of PBMCs proliferation assay. Black line: stimulated cells; dotted line: unstim-
ulated cells.Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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one experiment. These data indicate that DNA-HSP65 is
also able to activate the adaptive immune response lead-
ing to a Hsp65-specific cell proliferation.
Discussion
In this study we not only verified that the DNA vaccine
encoding the Mycobacterium leprae 65 kDa heat shock pro-
tein (DNA-HSP65) was uptaken by human macrophages
and DCs, but we also demonstrated that this vaccine
induced a distinct pattern of cytokine production. Addi-
tionally, we showed that DNA-HSP65 induced an up-reg-
ulation of costimulatory molecules, changing the cell
phenotype and improved the microbicidal activity of
macrophages against M. tuberculosis. On top of that, DNA-
HSP65 was able to induce specific cell proliferation.
The differential activation of macrophages and DCs
described here may be related to their ability to uptake the
vaccine. Despite the fact that almost 100% of macro-
phages were able to uptake DNA vaccine, our results
showed that a subpopulation of DCs presented the high-
est ability to uptake the vaccine. Different endocytic
mechanisms involving distinct receptors in each cell type
may be related. Recently, it was described that a human
keratinocyte cell-line is able to uptake plasmid DNA by a
mechanism that involves macropinocytosis and binding
to two DNA-binding cell surface proteins, ezrin and
moesin [28]. In addition, some specific receptors, such as
the macrophage class A scavenger receptor MARCO (mac-
rophage receptor with a collagenous structure) are
involved in the endocytosis of plasmid DNA by mouse
peritoneal macrophages [29]. Since different receptors
may be involved with the uptake of plasmid DNA, it is
possible that distinct signalling pathways occur. Moreo-
ver, it was recently reported that the nature of pDCs
response to TLR9 activation depends primarily on the
intracellular compartment in which the CpG-TLR9 inter-
action occurs. The interaction of CpG-TLR9 at early endo-
somes induces IFN-alpha by pDCs, whereas CpG-TLR9
interaction at late endosomes promotes maturation of
pDCs [30]. Thus, it is possible that monocyte-derived
macrophages and DCs uptake DNA vaccine by different
routes. Consequently, DNA may localize in distinct cellu-
lar compartments, generating different biological
responses.
The type of DCs used in this study is also discussed. It was
previously described that monocyte-derived DCs do not
express TLR9 [31], so it was reasonable to assume that
they were not activated by CpG-ODN. However, a recent
report showed that monocyte-derived DCs contain TLR9
protein in amounts comparable with pDCs [32]. We have
also observed that monocyte-derived DCs express intrac-
ellular TLR9 protein. These authors also described that
monocyte-derived DCs captured CpG-ODN, secreted IFN-
alpha and that CpG-ODN-stimulated DCs primed alloge-
neic CD4+ T cells for proliferation and differentiation into
IFN-gamma-secreting Th1 cells [32]. These data are in
agreement with our results. However, we did not observe
the IFN-alpha production by monocyte-derived DCs. In
parallel with the cellular activation, we also verified that
macrophages and DCs exhibited different microbicidal
ability after being stimulated with DNA-HSP65. Despite
the fact that macrophages stimulated with DNA-HSP65
were more effective to restrict the M. tuberculosis growth
compared to DCs under the same stimulation, unstimu-
lated macrophages presented higher mycobacterial
growth than DCs. Two different groups have described
that unstimulated DCs are more permissive to M. tubercu-
losis growth than macrophages [33,34]. However, an in
vivo study that evaluated the DC functions after mycobac-
terial infection showed that BCG bacilli survive and
remain stable in number inside DCs, suggesting that these
cells may represent a hidden reservoir for mycobacteria
[35]. Our data are concurring with these later authors.
Recent studies support the hypothesis that macrophages
and DCs may have different roles during TB infection
[36]. Therefore, the possibility of DNA-HSP65-stimulated
macrophages and DCs present predetermined roles can-
not be excluded. Giacomini et al. [36] described that after
M. tuberculosis infection, the proinflammatory cytokines
TNF-alpha, IL-1 and IL-6 and the immunosuppressive
cytokine IL-10 were secreted mainly by monocyte-derived
macrophages, while IL-12 was secreted almost exclusively
by monocyte-derived DCs. They suggested that during M.
tuberculosis infection macrophages secrete proinflamma-
tory cytokines, whereas DCs are primarily involved in
inducing antimycobacterial T cell immune response.
Despite the fact that we studied the interaction of these
APCs with a DNA vaccine, the same pattern of cellular
activation reported by Giacomini et al. [36] was observed
herein. On the other hand, other studies have shown that
M. tuberculosis and M. bovis inhibit IL-12 secretion [37,38].
In this context, the observation that DNA-HSP65 stimu-
lated IL-12 secretion by DCs is interesting and appears to
support the hypothesis that this plasmid used as vaccine
could be more useful to obtain a protective immune
response than the infection itself.
It is important to mention that the stimulation induced by
DNA vector was as effective as DNA vaccine regarding the
cytokine production, expression of surface markers and
microbicidal activity. This may be explained by the
hypothesis that the immunostimulatory properties of
either DNA vaccine or DNA vector described here are
attributed to the presence of CpG ODN on plasmid back-
bone. A pattern consistent with CpG-driven immune acti-
vation was suggested by the comparable immune
responses elicited by a vaccine encoding the circumsporo-Genetic Vaccines and Therapy 2008, 6:3 http://www.gvt-journal.com/content/6/1/3
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zoite protein of Plasmodium yoelii and the plasmid back-
bone alone [39]. Our data are in agreement with these
authors.
Finally, we demonstrated that DNA-HSP65 was able to
induce significant proliferation of PBMC. Our results sug-
gest that the cells that proliferated in response to DNA-
HSP65 stimulation were Hsp65-specific, since both
unstimulated and DNA vector-stimulated PBMC exhib-
ited similar proliferation response. From the nine healthy
individuals tested in these assays, six were tested for their
reactivity against mycobacterial antigens (PPD test): three
individuals were PPD+ and three were PPD-. We found
that both individuals – PPD+ and PPD- – displayed similar
cell proliferation after stimulation with DNA-HSP65. In
tuberculosis and leprosy patients, Hsp65-specific T cells
have repeatedly been identified. Interestingly, T cells with
reactivity to Hsp65 have also been identified in normal
healthy individuals lacking any clinical signs of disease
[40]. This demonstrates that Hsp65 is a prominent anti-
gen that triggers a significant portion of the immune
response, irrespective of whether the individual have
already encountered or not this antigen.
Conclusion
Overall, our results suggest that DNA-HSP65 is able to
activate human immune response by different ways.
Despite the fact that in vitro studies do not exactly mimic
the microenvironmental conditions of in vivo studies, they
do provide an approximation of how human APCs are
activated in vivo. The data reported herein provide clues to
the establishment of new strategies to improve APCs
microbicidal activity. Finally, our findings have important
implications for the design of new strategies based on
immunotherapies and, consequently, on modulation of
immune response in TB.
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